Title : Molecular mechanisms of microvascular failure in central nervous system injury--synergistic roles of NKCC1 and SUR1/TRPM4.

Pub. Date : 2010 Sep

PMID : 20035575






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Bumetanide and glibenclamide are 2 well-characterized, safe, FDA-approved drugs that inhibit NKCC1 and the SUR1/TRPM4 channel, respectively. Glyburide transient receptor potential cation channel, subfamily M, member 4 Rattus norvegicus
2 Given the mechanistic and temporal differences by which NKCC1 and the SUR1/TRPM4 channel contribute to the pathophysiological mechanisms of these events, combination therapy with bumetanide and glibenclamide may yield critical synergy in preventing injury-associated capillary failure. Glyburide transient receptor potential cation channel, subfamily M, member 4 Rattus norvegicus